title: [Serious organ damage and intractable clinical conditions in rheumatic and connective tissue disease--progress in pathophysiology and treatment. Topics: II. Clinical conditions special attention needed to be paid to; 4. Macrophage activating syndrome and hemophagocytic syndrome].
authors.affiliation: First Department of Internal Medicine, Kyorin University School of Medicine, Japan.
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Komagata
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage; D003240:Connective Tissue Diseases / Q000150:complications*; D016572:Cyclosporine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D051359:Lymphohistiocytosis, Hemophagocytic / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D055501:Macrophage Activation Syndrome / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*; D008727:Methotrexate / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D020551:Pulse Therapy, Drug; D055545:gamma-Globins / Q000008:administration & dosage
chemical_list: D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D055545:gamma-Globins; D005047:Etoposide; D003907:Dexamethasone; D016572:Cyclosporine; D008775:Methylprednisolone; D008727:Methotrexate